NCT01222442View on ClinicalTrials.gov

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Chronic Obstructive Pulmonary DiseaseLung Disease
Interventions
DRUG

AZD3199

Single dose, oral inhalation

DRUG

Moxifloxacin

Single dose, oral encapsulated tablet

OTHER

Placebo comparator

Single dose, oral inhalation

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01222442 - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart | Biotech Hunter | Biotech Hunter